Racura scientists develop cardioprotection blood test to support key trial

Racura Oncology scientists have developed a novel blood-based molecular test designed to assess the cardioprotective effects of its lead drug candidate RC220.

Read article here.

Latest Posts

L36, 1 Macquarie Place Sydney NSW 2000
E: info@racuraoncology.com T: +61 2 8051 3043
© 2026 Racura Oncology | Privacy Policy
Sign up to receive the most recent news and updates
Sign up to receive the most recent news and updates
Racura Oncology
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.